Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | GPR18 | Q14330 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8217007 | 0.98 | FAAH (0.43) | FAAHALDH1A1PTPN1ACEMAPT | |
| SCHEMBL22887712 | 0.95 | FAAH (0.42) | FAAHALDH1A1PTPN1ACEMAPT | |
| SCHEMBL468980 | 0.95 | FAAH (0.42) | FAAHALDH1A1PTPN1ACEMAPT | |
| SCHEMBL2804264 | 0.79 | PTPN1 (0.55) | FAAHALDH1A1PTPN1MAPTTDP1 | |
| SCHEMBL2808310 | 0.79 | PTPN1 (0.60) | FAAHALDH1A1PTPN1MAPTTDP1 | |
| SCHEMBL3253304 | 0.79 | PHF8 (0.55) | FAAHALDH1A1PTPN1MAPTTDP1 | |
| SCHEMBL75812 | 0.79 | — | — | |
| SCHEMBL18618642 | 0.79 | FAAH (0.62) | FAAHALDH1A1PTPN1MAPTTDP1 | |
| SCHEMBL16108691 | 0.78 | ECE1 (0.56) | FAAHACEMMEHDAC3HDAC4 | |
| SCHEMBL11306604 | 0.78 | CA1 (0.38) | ALDH1A1ACERECQLHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118576786-A | Multifunctional hydrophilic lubricating coating and preparation method thereof | 四川大学华西医院 | 2024-09-03 | — | — | CN | claimed |
| EP-4405042-A1 | INHIBITORS OF PROTECTIVE LOSS-OF-FUNCTION GENES FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE | Regeneron Pharmaceuticals, Inc. (US) | 2024-07-31 | — | — | EP | claimed |
| CN-116272705-B | Preparation method and application of core-shelled nanocluster hydrogel microsphere | 广东工业大学 | 2023-09-19 | — | — | CN | claimed |
| CN-116686923-A | Sea buckthorn stachyose beverage and production process thereof | 杭州懿满天下健康管理有限公司 | 2023-09-05 | — | — | CN | claimed |
| CN-115626808-B | Environment-friendly high-strength modified phosphogypsum regenerated lightweight aggregate and preparation method and application thereof | 湖北聚海环境科技有限公司 | 2023-08-11 | — | — | CN | claimed |
| CN-116272705-A | Preparation method and application of core-shelled nanocluster hydrogel microsphere | 广东工业大学 | 2023-06-23 | — | — | CN | claimed |
| US-20230133885-A1 | NEW SYNTHETIC METHODS USING NATIVE CHEMICAL LIGATION IN FLOW | THE UNIVERSITY OF SYDNEY (AU) | 2023-05-04 | — | — | US | claimed |
| US-20230107173-A1 | Methods Of Treating Chronic Kidney Disease (CKD) With Inhibitors Of Protective Loss-Of-Function Genes | REGENERON PHARMA (US) | 2023-04-06 | — | — | US | claimed |
| WO-2023049787-A1 | INHIBITORS OF PROTECTIVE LOSS-OF-FUNCTION GENES FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE | REGENERON PHARMACEUTICALS, INC. (US) | 2023-03-30 | — | — | WO | claimed |
| CN-115626808-A | Environment-friendly high-strength modified phosphogypsum regenerated light aggregate and preparation method and application thereof | 湖北聚海环境科技有限公司 | 2023-01-20 | — | — | CN | claimed |
| EP-0124925-B1 | DERIVATIVES OF D-2-(6-METHOXY-2-NAPHTHYL)-PROPIONIC ACID HAVING THERAPEUTICAL ACTIVITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FARMA RESA SrL (IT) | 1986-11-26 | — | — | EP | claimed |
| EP-0096013-B1 | SALTS OF ERYTHROMYCIN SHOWING A COMBINED THERAPEUTIC ACTIVITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | NUOVO CONSORZIO SANITARIO NAZIONALE (IT) | 1986-07-23 | — | — | EP | claimed |
| EP-0156514-A2 | Photoconductive devices containing perylene dye compositions | XEROX CORPORATION (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0052909-B1 | DERIVATIVE OF ALFA-MERCAPTOPROPIONILGLICINE HAVING THERAPEUTICAL ACTIVITY, PROCESS FOR ITS PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS | Real S.a.s. di Alberto Reiner & C. (IT) | 1985-04-10 | — | — | EP | claimed |
| US-4414145-A | Preparation and use of a 195M-AU-containing liquid | BYK-MILLINKCRODT CIL B.V. (NL) | 1983-11-08 | — | — | US | claimed |
| EP-0087397-A2 | Propionylglycine derivative, process for its preparation and therapeutic compositions which contain it as the active principle | Farmatis S.r.l. (IT) | 1983-08-31 | — | — | EP | claimed |
| EP-0015544-B1 | DERIVATIVES OF THE MERCAPTOPROPIONAMIDO-ACETIC ACID, PROCESS FOR THE PREPARATION THEREOF AND COMPOSITIONS | ZAMBON S.p.A. (IT) | 1983-01-05 | — | — | EP | claimed |
| EP-0013261-B1 | GUAIACOL ESTERS OF ALPHA- AND BETA-MERCAPTOPROPIONYLALANINE AND ALPHA- AND BETA-MERCAPTOPROPIONYLGLYCINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1982-12-01 | — | — | EP | claimed |
| US-4346234-A | Process for the preparation of the sodium salt of mercaptopropionylglycine | GARGANI PIETRO | 1982-08-24 | — | — | US | claimed |
| EP-0015544-A2 | Derivatives of the mercaptopropionamido-acetic acid, process for the preparation thereof and compositions | ZAMBON S.p.A. (IT) | 1980-09-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133885-A1 | NEW SYNTHETIC METHODS USING NATIVE CHEMICAL LIGATION IN FLOW | SCLY, SRM, SELENOI | FAAH 2997/4885ALDH1A1 2296/4885PTPN1 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.